603262.SH
技源集团
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 18.40
+4.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 1.0B | 891.9M | 947.2M |
| Cost of Revenue | 618.8M | 628.4M | 566.1M | 506.3M | 579.0M |
| Gross Profit | 449.4M | 464.7M | 435.8M | 385.6M | 368.2M |
| Operating Expenses | |||||
| R&D Expense | 55.5M | 52.5M | 49.7M | 43.0M | 42.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 156.1M | 160.1M | 121.2M | 109.6M | 105.7M |
| Selling & Marketing Expense | 80.0M | 77.7M | 63.5M | 54.3M | 44.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 306.7M | 295.2M | 236.2M | 206.1M | 196.9M |
| Cost and Expenses | 925.5M | 923.6M | 802.2M | 712.5M | 775.9M |
| Operating Income (EBIT) | 130.9M | 152.5M | 200.1M | 184.7M | 174.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 130.0M | 152.5M | 200.1M | 184.7M | 168.3M |
| Income Tax Expense | 14.6M | 17.7M | 24.7M | 24.2M | 24.7M |
| Bottom Line | |||||
| Net Income | 114.0M | 133.7M | 174.4M | 160.0M | 142.1M |
| Earnings from Cont. Ops | 115.4M | 134.8M | 175.3M | 160.5M | 143.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 114.0M | 133.7M | 174.4M | 160.0M | 142.1M |
| Per Share | |||||
| Basic EPS | CN¥0.32 | CN¥0.36 | CN¥0.50 | CN¥0.46 | CN¥0.41 |
| Diluted EPS | CN¥0.32 | CN¥0.36 | CN¥0.50 | CN¥0.46 | CN¥0.41 |
| Revenue Per Share | CN¥2.80 | CN¥2.94 | CN¥2.87 | CN¥2.56 | CN¥2.73 |
| Shares | |||||
| Basic Shares Outstanding | 382.1M | 371.4M | 348.9M | 347.9M | 346.5M |
| Diluted Shares Outstanding | 382.1M | 371.4M | 348.9M | 347.9M | 346.5M |
| Profitability Metrics | |||||
| EBITDA | 73.0M | 194.6M | 238.8M | 220.6M | 204.2M |
| D&A | 8.8M | 42.1M | 38.7M | 35.9M | 30.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026